Generic
Lenograstim
1 brands available in the market
At a glance
Lenograstim is a granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of neutropenia after chemotherapy or bone marrow transplantation and to aid in peripheral blood progenitor cell (PBPC) collection.
Description
Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor (rHuG-CSF). It significantly accelerates neutrophil recovery after chemotherapy, reducing the incidence of infection and hospital stay. It also assists neutrophil recovery after bone marrow transplantation and stimulates production of peripheral blood stem cells for autologous transfusion after aggressive chemotherapy.
Indications
- Reduction of neutropenia duration (after myeloablative therapy and BMT or after cytotoxic chemotherapy)
- Peripheral blood progenitor cell (PBPC) mobilization (patients and healthy donors)
Therapeutic class
Haematopoietic Agents
Pharmacological class
Granulocyte Colony Stimulating Factor (G-CSF)
Pharmacology
Lenograstim is recombinant human G-CSF that stimulates neutrophil production and release. It reduces the duration and severity of neutropenia after chemotherapy or BMT and aids in PBPC collection.
Mechanism of action
Stimulates neutrophil production and peripheral blood stem cell collection.
Dosage
Adult Dose:
- After BMT or Chemotherapy: 19.2 MIU (150 µg) per m²/day or 0.64 MIU (5 µg) per kg/day
- PBPC Collection (Lenograstim alone): 1.28 MIU (10 µg) per kg/day
Children (>2 years): Same dose as adults
Administration
- Administered as subcutaneous (SC) injection
- Should be given in collaboration with an experienced oncology/haematology centre
Missed dose
Not generally applicable (administered by medical professional); consult doctor if needed.
Side effects
Common Side Effects:
- Musculoskeletal pain, bone pain
- Splenic enlargement
- Nausea, fever
- Thrombocytopenia, anemia
- Epistaxis
- Headache, diarrhea, dysuria
- Osteoporosis, cutaneous vasculitis, anorexia
- Sweet's syndrome, toxic epidermal necrolysis
Precautions & warnings
- Only for patients with neutropenia or those undergoing PBPC collection
- Monitor neutrophil count; reduce dose or discontinue if excessive increase occurs
- Take complete medical history including allergies and drug hypersensitivity
- Do not administer concurrently with cytotoxic chemotherapy
Contraindications
- Hypersensitivity to Lenograstim or any excipients
- Myeloid malignancy (other than de novo AML)
- De novo AML under age 55 years
- De novo AML with good cytogenetics
Drug interactions
- Increased risk of myelosuppression with myelosuppressive antineoplastic agents
- Increased pulmonary toxicity with bleomycin and cyclophosphamide
Food interactions
No food interactions applicable (parenteral use).
Use in pregnancy
Use in Pregnancy: No adequate data in pregnant women; animal studies have shown reproductive toxicity. Use only if clearly necessary.
Use in lactation
Use in Lactation: Unknown if excreted in human milk; excretion in animal milk not studied. Breastfeeding should be discontinued during therapy.
Pediatric use
Children over 2 years: same dose as adults; safety not established in children under 2 years.
Geriatric use
Limited number of elderly patients up to 70 years included in studies; no specific dosage recommendations can be made.
Renal / hepatic impairment
No specific precautions for renal or hepatic impairment.
Overdose effects
No specific overdose information available; symptomatic and supportive measures should be employed.
Storage conditions
Store in a cool and dry place; keep out of reach of children.
Chemical structure
Lenograstim